Ipratropium Adultes Sandoz (Ipratropium Bromide Anhydrous)

Ipratropium bromide is an inhaled anticholinergic bronchodilator used in the management of obstructive airway diseases.

• Chronic obstructive pulmonary disease (COPD): improves airflow and reduces dyspnea in stable patients.
• Asthma: provides bronchodilation to relieve bronchoconstriction during maintenance therapy.
• Bronchospasm associated with COPD or asthma: offers rapid relief of airway narrowing.
• Exercise‑induced bronchoconstriction: reduces symptoms during physical activity.
• Acute exacerbations of COPD: aids in symptom control as adjunct therapy.

• Ipratropium bromide acts as a competitive antagonist at muscarinic (M1 and M3) acetylcholine receptors located on airway smooth‑muscle cells. By blocking acetylcholine binding, it prevents intracellular calcium increase, inhibiting bronchoconstriction. The resulting relaxation of bronchial smooth muscle increases airway caliber, improving ventilation. Its action is localized to the respiratory tract because the compound is poorly absorbed systemically, limiting systemic anticholinergic effects.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and related to its anticholinergic activity.

Common Side Effects

• Dry mouth: reduced salivary secretion causing throat discomfort and difficulty swallowing.
• Cough: irritation of the airway during inhalation that may persist for several minutes.
• Taste disturbance: altered or unpleasant taste after use, sometimes described as bitter.
• Headache: mild tension‑type headache that usually resolves without intervention.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing that requires immediate medical attention.
• Angioedema: swelling of the face, lips or tongue that may compromise the airway.
• Severe allergic reaction: rash, hives, or anaphylaxis requiring urgent care.

Before prescribing Ipratropium Adultes Sandoz, clinicians should consider several safety aspects.

• Assess respiratory status before initiating therapy: confirm diagnosis and baseline lung function.
• Monitor for anticholinergic effects: watch for dry mouth, urinary retention, or blurred vision.
• Use with caution in patients with narrow‑angle glaucoma: may increase intra‑ocular pressure.
• Avoid in individuals with known hypersensitivity to ipratropium or formulation excipients.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Ipratropium bromide can interact with other medications, necessitating awareness of potential additive effects.

Major Interactions (Avoid)

• Concurrent use with other anticholinergic inhalers: may increase anticholinergic burden and side‑effects.

Moderate Interactions (Monitor Closely)

• Beta2‑agonists – additive bronchodilator effect may require dose adjustment.
• MAO inhibitors – possible enhancement of cholinergic side effects.
• Diuretics – may exacerbate dry mouth and electrolyte imbalance.
• Theophylline – monitor serum levels as bronchodilator synergy can affect metabolism.